GLP-1 Receptor Agonist Induced Eustachian Tube Dysfunction: Database and Systematic Review of Otolaryngologic Adverse Events.

Pak KY, Cutri RM, Nadeem W, Kothari D, Wong YT, Wu AW, Miller ME

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology1 Jan 2025Cited by 7 (Europe PMC)

PMID39666743DOI10.1097/mao.0000000000004373PepBankPUB-39666743

Publisher page PubMedAsk about this study

Jump to 36 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study36

2 results from studies that gave the peptide. 2 results from people.

01HumanObservational studySafety outcome
In the FAERS database analysis, the potential ETD-related adverse-report proportion was 1.16% for liraglutide; this was not a clinical-incidence estimate.
In plain wordsIn safety-report data, possible eustachian-tube dysfunction made up 1.16% of liraglutide reports; this was not a clinical-risk estimate.
Peptide
Liraglutide
Outcome
Not applicablePotential eustachian tube dysfunction adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
Potential eustachian tube dysfunction adverse event proportion
1.16%
liraglutide
Source sentences
Summary
The greatest proportion of potential ETD-related AEs occurred with exenatide (1.52%) followed by semaglutide (1.17%) and liraglutide (1.16%).
1 context sentence(design, population, supporting numbers)
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
Report a problemFND-3966674313
02HumanObservational studySafety outcome
In the FAERS database analysis, the potential ETD-related adverse-report proportion was 1.17% for semaglutide; this was not a clinical-incidence estimate.
In plain wordsIn safety-report data, possible eustachian-tube dysfunction made up 1.17% of semaglutide reports; this was not a clinical-risk estimate.
Peptide
Semaglutide
Outcome
Not applicablePotential eustachian tube dysfunction adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Measurements
Potential eustachian tube dysfunction adverse event proportion
1.17%
semaglutide
Source sentences
Summary
The greatest proportion of potential ETD-related AEs occurred with exenatide (1.52%) followed by semaglutide (1.17%) and liraglutide (1.16%).
1 context sentence(design, population, supporting numbers)
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
Report a problemFND-3966674314

Studies that did not test the peptide alone34

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

03HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In this review, nasopharyngitis was among the top identified otologic side effects of GLP-1 receptor agonists as a class.
In plain wordsIn this review, nasopharyngitis was among the top reported GLP-1 drug ear-related side effects.
Peptide
Liraglutide
Outcome
Not applicableNasopharyngitis
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
The top 3 identified otologic side effects included nasopharyngitis, sinusitis, unspecified dizziness.
3 context sentences(design, population, supporting numbers)
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
Summary · context
We also performed a systematic review using the PRISMA guidelines.
Summary · context
The systematic review using PRISMA guidelines yielded 1,490 initial articles, of which 937 were screened and 10 met the inclusion criteria.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3966674315
04HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In this review, nasopharyngitis was among the top identified otologic side effects of GLP-1 receptor agonists as a class.
In plain wordsIn this review, nasopharyngitis was among the top reported GLP-1 drug ear-related side effects.
Peptide
Semaglutide
Outcome
Not applicableNasopharyngitis
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
The top 3 identified otologic side effects included nasopharyngitis, sinusitis, unspecified dizziness.
3 context sentences(design, population, supporting numbers)
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
Summary · context
We also performed a systematic review using the PRISMA guidelines.
Summary · context
The systematic review using PRISMA guidelines yielded 1,490 initial articles, of which 937 were screened and 10 met the inclusion criteria.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3966674316
05HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In this review, sinusitis was among the top identified otologic side effects of GLP-1 receptor agonists as a class.
In plain wordsIn this review, sinusitis was among the top reported GLP-1 drug ear-related side effects.
Peptide
Liraglutide
Outcome
Not applicableSinusitis
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
The top 3 identified otologic side effects included nasopharyngitis, sinusitis, unspecified dizziness.
3 context sentences(design, population, supporting numbers)
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
Summary · context
We also performed a systematic review using the PRISMA guidelines.
Summary · context
The systematic review using PRISMA guidelines yielded 1,490 initial articles, of which 937 were screened and 10 met the inclusion criteria.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3966674317
06HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In this review, sinusitis was among the top identified otologic side effects of GLP-1 receptor agonists as a class.
In plain wordsIn this review, sinusitis was among the top reported GLP-1 drug ear-related side effects.
Peptide
Semaglutide
Outcome
Not applicableSinusitis
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
The top 3 identified otologic side effects included nasopharyngitis, sinusitis, unspecified dizziness.
3 context sentences(design, population, supporting numbers)
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
Summary · context
We also performed a systematic review using the PRISMA guidelines.
Summary · context
The systematic review using PRISMA guidelines yielded 1,490 initial articles, of which 937 were screened and 10 met the inclusion criteria.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3966674318
07HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In this review, unspecified dizziness was among the top identified otologic side effects of GLP-1 receptor agonists as a class.
In plain wordsIn this review, unspecified dizziness was among the top reported GLP-1 drug ear-related side effects.
Peptide
Liraglutide
Outcome
Not applicableUnspecified dizziness
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
The top 3 identified otologic side effects included nasopharyngitis, sinusitis, unspecified dizziness.
3 context sentences(design, population, supporting numbers)
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
Summary · context
We also performed a systematic review using the PRISMA guidelines.
Summary · context
The systematic review using PRISMA guidelines yielded 1,490 initial articles, of which 937 were screened and 10 met the inclusion criteria.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3966674319
08HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In this review, unspecified dizziness was among the top identified otologic side effects of GLP-1 receptor agonists as a class.
In plain wordsIn this review, unspecified dizziness was among the top reported GLP-1 drug ear-related side effects.
Peptide
Semaglutide
Outcome
Not applicableUnspecified dizziness
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
The top 3 identified otologic side effects included nasopharyngitis, sinusitis, unspecified dizziness.
3 context sentences(design, population, supporting numbers)
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
Summary · context
We also performed a systematic review using the PRISMA guidelines.
Summary · context
The systematic review using PRISMA guidelines yielded 1,490 initial articles, of which 937 were screened and 10 met the inclusion criteria.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3966674320
09HumanNot a test of Liraglutide aloneObservational studySafety outcome
In the FAERS analysis, 958 (0.99%) otologic adverse events were reported among 97,237 GLP-1 receptor agonist adverse events.
In plain wordsIn the FAERS analysis, 958 ear-related reports, or 0.99%, occurred among 97,237 GLP-1 drug reports.
Peptide
Liraglutide
Outcome
Not applicableOtologic adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Otologic adverse-event reports
958 reports
pooled GLP-1RA FAERS reports; total 97,237 preserved in statement/primary quote
Otologic adverse-event report proportion
0.99%
of pooled GLP-1RA reports
Source sentences
Summary
The total number of adverse events (AEs) with GLP-1 RAs was 97,237. The proportion of otologic AEs was 958 (0.99%): 515 hypoacusis, 203 vertigo, 97 deafness, 93 tinnitus, 22 ear pain, 21 motion sickness, 5 hyperacusis, 2 ear fullness, and 0 autophony.
1 context sentence(design, population, supporting numbers)
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3966674305
10HumanNot a test of Semaglutide aloneObservational studySafety outcome
In the FAERS analysis, 958 (0.99%) otologic adverse events were reported among 97,237 GLP-1 receptor agonist adverse events.
In plain wordsIn the FAERS analysis, 958 ear-related reports, or 0.99%, occurred among 97,237 GLP-1 drug reports.
Peptide
Semaglutide
Outcome
Not applicableOtologic adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Otologic adverse-event reports
958 reports
pooled GLP-1RA FAERS reports; total 97,237 preserved in statement/primary quote
Otologic adverse-event report proportion
0.99%
of pooled GLP-1RA reports
Source sentences
Summary
The total number of adverse events (AEs) with GLP-1 RAs was 97,237. The proportion of otologic AEs was 958 (0.99%): 515 hypoacusis, 203 vertigo, 97 deafness, 93 tinnitus, 22 ear pain, 21 motion sickness, 5 hyperacusis, 2 ear fullness, and 0 autophony.
1 context sentence(design, population, supporting numbers)
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3966674306
11HumanNot a test of Liraglutide aloneObservational studySafety outcome
In this review, hypoacusis was reported among otologic adverse events with GLP-1 receptor agonists as a class.
In plain wordsIn this review, reduced hearing was reported among ear-related GLP-1 drug side effects.
Peptide
Liraglutide
Outcome
Not applicableHypoacusis
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Hypoacusis adverse events
515 adverse events
GLP-1 receptor agonists
Source sentences
Summary
The proportion of otologic AEs was 958 (0.99%): 515 hypoacusis, 203 vertigo, 97 deafness, 93 tinnitus, 22 ear pain, 21 motion sickness, 5 hyperacusis, 2 ear fullness, and 0 autophony.
2 context sentences(design, population, supporting numbers)
Summary · context
The total number of adverse events (AEs) with GLP-1 RAs was 97,237.
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3966674307
12HumanNot a test of Semaglutide aloneObservational studySafety outcome
In this review, hypoacusis was reported among otologic adverse events with GLP-1 receptor agonists as a class.
In plain wordsIn this review, reduced hearing was reported among ear-related GLP-1 drug side effects.
Peptide
Semaglutide
Outcome
Not applicableHypoacusis
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Hypoacusis adverse events
515 adverse events
GLP-1 receptor agonists
Source sentences
Summary
The proportion of otologic AEs was 958 (0.99%): 515 hypoacusis, 203 vertigo, 97 deafness, 93 tinnitus, 22 ear pain, 21 motion sickness, 5 hyperacusis, 2 ear fullness, and 0 autophony.
2 context sentences(design, population, supporting numbers)
Summary · context
The total number of adverse events (AEs) with GLP-1 RAs was 97,237.
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3966674308
13HumanNot a test of Liraglutide aloneObservational studySafety outcome
In this review, vertigo was reported among otologic adverse events with GLP-1 receptor agonists as a class.
In plain wordsIn this review, vertigo was reported among ear-related GLP-1 drug side effects.
Peptide
Liraglutide
Outcome
Not applicableVertigo
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Vertigo adverse events
203 adverse events
GLP-1 receptor agonists
Source sentences
Summary
The proportion of otologic AEs was 958 (0.99%): 515 hypoacusis, 203 vertigo, 97 deafness, 93 tinnitus, 22 ear pain, 21 motion sickness, 5 hyperacusis, 2 ear fullness, and 0 autophony.
2 context sentences(design, population, supporting numbers)
Summary · context
The total number of adverse events (AEs) with GLP-1 RAs was 97,237.
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3966674309
14HumanNot a test of Semaglutide aloneObservational studySafety outcome
In this review, vertigo was reported among otologic adverse events with GLP-1 receptor agonists as a class.
In plain wordsIn this review, vertigo was reported among ear-related GLP-1 drug side effects.
Peptide
Semaglutide
Outcome
Not applicableVertigo
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Vertigo adverse events
203 adverse events
GLP-1 receptor agonists
Source sentences
Summary
The proportion of otologic AEs was 958 (0.99%): 515 hypoacusis, 203 vertigo, 97 deafness, 93 tinnitus, 22 ear pain, 21 motion sickness, 5 hyperacusis, 2 ear fullness, and 0 autophony.
2 context sentences(design, population, supporting numbers)
Summary · context
The total number of adverse events (AEs) with GLP-1 RAs was 97,237.
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3966674310
15HumanNot a test of Liraglutide aloneObservational studySafety outcome
In this review, deafness was reported among otologic adverse events with GLP-1 receptor agonists as a class.
In plain wordsIn this review, deafness was reported among ear-related GLP-1 drug side effects.
Peptide
Liraglutide
Outcome
Not applicableDeafness
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Deafness adverse events
97 adverse events
GLP-1 receptor agonists
Source sentences
Summary
The proportion of otologic AEs was 958 (0.99%): 515 hypoacusis, 203 vertigo, 97 deafness, 93 tinnitus, 22 ear pain, 21 motion sickness, 5 hyperacusis, 2 ear fullness, and 0 autophony.
2 context sentences(design, population, supporting numbers)
Summary · context
The total number of adverse events (AEs) with GLP-1 RAs was 97,237.
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3966674311
16HumanNot a test of Semaglutide aloneObservational studySafety outcome
In this review, deafness was reported among otologic adverse events with GLP-1 receptor agonists as a class.
In plain wordsIn this review, deafness was reported among ear-related GLP-1 drug side effects.
Peptide
Semaglutide
Outcome
Not applicableDeafness
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Deafness adverse events
97 adverse events
GLP-1 receptor agonists
Source sentences
Summary
The proportion of otologic AEs was 958 (0.99%): 515 hypoacusis, 203 vertigo, 97 deafness, 93 tinnitus, 22 ear pain, 21 motion sickness, 5 hyperacusis, 2 ear fullness, and 0 autophony.
2 context sentences(design, population, supporting numbers)
Summary · context
The total number of adverse events (AEs) with GLP-1 RAs was 97,237.
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3966674312
17HumanNot a test of Liraglutide aloneObservational studySafety outcome
In the FAERS analysis, 93 tinnitus adverse events were reported among GLP-1 receptor agonist adverse events.
In plain wordsIn the FAERS analysis, 93 tinnitus reports occurred with GLP-1 drugs as a class.
Peptide
Liraglutide
Outcome
Not applicableTinnitus adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Tinnitus adverse events
93 adverse events
GLP-1 receptor agonists
Source sentences
Summary
The proportion of otologic AEs was 958 (0.99%): 515 hypoacusis, 203 vertigo, 97 deafness, 93 tinnitus, 22 ear pain, 21 motion sickness, 5 hyperacusis, 2 ear fullness, and 0 autophony.
2 context sentences(design, population, supporting numbers)
Summary · context
The total number of adverse events (AEs) with GLP-1 RAs was 97,237.
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3966674323
18HumanNot a test of Semaglutide aloneObservational studySafety outcome
In the FAERS analysis, 93 tinnitus adverse events were reported among GLP-1 receptor agonist adverse events.
In plain wordsIn the FAERS analysis, 93 tinnitus reports occurred with GLP-1 drugs as a class.
Peptide
Semaglutide
Outcome
Not applicableTinnitus adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Tinnitus adverse events
93 adverse events
GLP-1 receptor agonists
Source sentences
Summary
The proportion of otologic AEs was 958 (0.99%): 515 hypoacusis, 203 vertigo, 97 deafness, 93 tinnitus, 22 ear pain, 21 motion sickness, 5 hyperacusis, 2 ear fullness, and 0 autophony.
2 context sentences(design, population, supporting numbers)
Summary · context
The total number of adverse events (AEs) with GLP-1 RAs was 97,237.
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3966674324
19HumanNot a test of Liraglutide aloneObservational studySafety outcome
In the FAERS analysis, 22 ear-pain adverse events were reported among GLP-1 receptor agonist adverse events.
In plain wordsIn the FAERS analysis, 22 ear-pain reports occurred with GLP-1 drugs as a class.
Peptide
Liraglutide
Outcome
Not applicableEar pain adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Ear pain adverse events
22 adverse events
GLP-1 receptor agonists
Source sentences
Summary
The proportion of otologic AEs was 958 (0.99%): 515 hypoacusis, 203 vertigo, 97 deafness, 93 tinnitus, 22 ear pain, 21 motion sickness, 5 hyperacusis, 2 ear fullness, and 0 autophony.
2 context sentences(design, population, supporting numbers)
Summary · context
The total number of adverse events (AEs) with GLP-1 RAs was 97,237.
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3966674325
20HumanNot a test of Semaglutide aloneObservational studySafety outcome
In the FAERS analysis, 22 ear-pain adverse events were reported among GLP-1 receptor agonist adverse events.
In plain wordsIn the FAERS analysis, 22 ear-pain reports occurred with GLP-1 drugs as a class.
Peptide
Semaglutide
Outcome
Not applicableEar pain adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Ear pain adverse events
22 adverse events
GLP-1 receptor agonists
Source sentences
Summary
The proportion of otologic AEs was 958 (0.99%): 515 hypoacusis, 203 vertigo, 97 deafness, 93 tinnitus, 22 ear pain, 21 motion sickness, 5 hyperacusis, 2 ear fullness, and 0 autophony.
2 context sentences(design, population, supporting numbers)
Summary · context
The total number of adverse events (AEs) with GLP-1 RAs was 97,237.
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3966674326
21HumanNot a test of Liraglutide aloneObservational studySafety outcome
In the FAERS analysis, 21 motion-sickness adverse events were reported among GLP-1 receptor agonist adverse events.
In plain wordsIn the FAERS analysis, 21 motion-sickness reports occurred with GLP-1 drugs as a class.
Peptide
Liraglutide
Outcome
Not applicableMotion sickness adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Motion sickness adverse events
21 adverse events
GLP-1 receptor agonists
Source sentences
Summary
The proportion of otologic AEs was 958 (0.99%): 515 hypoacusis, 203 vertigo, 97 deafness, 93 tinnitus, 22 ear pain, 21 motion sickness, 5 hyperacusis, 2 ear fullness, and 0 autophony.
2 context sentences(design, population, supporting numbers)
Summary · context
The total number of adverse events (AEs) with GLP-1 RAs was 97,237.
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3966674327
22HumanNot a test of Semaglutide aloneObservational studySafety outcome
In the FAERS analysis, 21 motion-sickness adverse events were reported among GLP-1 receptor agonist adverse events.
In plain wordsIn the FAERS analysis, 21 motion-sickness reports occurred with GLP-1 drugs as a class.
Peptide
Semaglutide
Outcome
Not applicableMotion sickness adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Motion sickness adverse events
21 adverse events
GLP-1 receptor agonists
Source sentences
Summary
The proportion of otologic AEs was 958 (0.99%): 515 hypoacusis, 203 vertigo, 97 deafness, 93 tinnitus, 22 ear pain, 21 motion sickness, 5 hyperacusis, 2 ear fullness, and 0 autophony.
2 context sentences(design, population, supporting numbers)
Summary · context
The total number of adverse events (AEs) with GLP-1 RAs was 97,237.
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3966674328
23HumanNot a test of Liraglutide aloneObservational studySafety outcome
In the FAERS analysis, 5 hyperacusis adverse events were reported among GLP-1 receptor agonist adverse events.
In plain wordsIn the FAERS analysis, 5 hyperacusis reports occurred with GLP-1 drugs as a class.
Peptide
Liraglutide
Outcome
Not applicableHyperacusis adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Hyperacusis adverse events
5 adverse events
GLP-1 receptor agonists
Source sentences
Summary
The proportion of otologic AEs was 958 (0.99%): 515 hypoacusis, 203 vertigo, 97 deafness, 93 tinnitus, 22 ear pain, 21 motion sickness, 5 hyperacusis, 2 ear fullness, and 0 autophony.
2 context sentences(design, population, supporting numbers)
Summary · context
The total number of adverse events (AEs) with GLP-1 RAs was 97,237.
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3966674329
24HumanNot a test of Semaglutide aloneObservational studySafety outcome
In the FAERS analysis, 5 hyperacusis adverse events were reported among GLP-1 receptor agonist adverse events.
In plain wordsIn the FAERS analysis, 5 hyperacusis reports occurred with GLP-1 drugs as a class.
Peptide
Semaglutide
Outcome
Not applicableHyperacusis adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Hyperacusis adverse events
5 adverse events
GLP-1 receptor agonists
Source sentences
Summary
The proportion of otologic AEs was 958 (0.99%): 515 hypoacusis, 203 vertigo, 97 deafness, 93 tinnitus, 22 ear pain, 21 motion sickness, 5 hyperacusis, 2 ear fullness, and 0 autophony.
2 context sentences(design, population, supporting numbers)
Summary · context
The total number of adverse events (AEs) with GLP-1 RAs was 97,237.
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3966674330
25HumanNot a test of Liraglutide aloneObservational studySafety outcome
In the FAERS analysis, 2 ear-fullness adverse events were reported among GLP-1 receptor agonist adverse events.
In plain wordsIn the FAERS analysis, 2 ear-fullness reports occurred with GLP-1 drugs as a class.
Peptide
Liraglutide
Outcome
Not applicableEar fullness adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Ear fullness adverse events
2 adverse events
GLP-1 receptor agonists
Source sentences
Summary
The proportion of otologic AEs was 958 (0.99%): 515 hypoacusis, 203 vertigo, 97 deafness, 93 tinnitus, 22 ear pain, 21 motion sickness, 5 hyperacusis, 2 ear fullness, and 0 autophony.
2 context sentences(design, population, supporting numbers)
Summary · context
The total number of adverse events (AEs) with GLP-1 RAs was 97,237.
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3966674331
26HumanNot a test of Semaglutide aloneObservational studySafety outcome
In the FAERS analysis, 2 ear-fullness adverse events were reported among GLP-1 receptor agonist adverse events.
In plain wordsIn the FAERS analysis, 2 ear-fullness reports occurred with GLP-1 drugs as a class.
Peptide
Semaglutide
Outcome
Not applicableEar fullness adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Ear fullness adverse events
2 adverse events
GLP-1 receptor agonists
Source sentences
Summary
The proportion of otologic AEs was 958 (0.99%): 515 hypoacusis, 203 vertigo, 97 deafness, 93 tinnitus, 22 ear pain, 21 motion sickness, 5 hyperacusis, 2 ear fullness, and 0 autophony.
2 context sentences(design, population, supporting numbers)
Summary · context
The total number of adverse events (AEs) with GLP-1 RAs was 97,237.
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3966674332
27HumanNot a test of Liraglutide aloneObservational studySafety outcome
In the FAERS analysis, 0 autophony adverse events were reported among GLP-1 receptor agonist adverse events.
In plain wordsIn the FAERS analysis, no autophony reports occurred with GLP-1 drugs as a class.
Peptide
Liraglutide
Outcome
Not applicableAutophony adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Autophony adverse events
0 adverse events
GLP-1 receptor agonists
Source sentences
Summary
The proportion of otologic AEs was 958 (0.99%): 515 hypoacusis, 203 vertigo, 97 deafness, 93 tinnitus, 22 ear pain, 21 motion sickness, 5 hyperacusis, 2 ear fullness, and 0 autophony.
2 context sentences(design, population, supporting numbers)
Summary · context
The total number of adverse events (AEs) with GLP-1 RAs was 97,237.
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3966674333
28HumanNot a test of Semaglutide aloneObservational studySafety outcome
In the FAERS analysis, 0 autophony adverse events were reported among GLP-1 receptor agonist adverse events.
In plain wordsIn the FAERS analysis, no autophony reports occurred with GLP-1 drugs as a class.
Peptide
Semaglutide
Outcome
Not applicableAutophony adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Measurements
Autophony adverse events
0 adverse events
GLP-1 receptor agonists
Source sentences
Summary
The proportion of otologic AEs was 958 (0.99%): 515 hypoacusis, 203 vertigo, 97 deafness, 93 tinnitus, 22 ear pain, 21 motion sickness, 5 hyperacusis, 2 ear fullness, and 0 autophony.
2 context sentences(design, population, supporting numbers)
Summary · context
The total number of adverse events (AEs) with GLP-1 RAs was 97,237.
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3966674334
29HumanNot a test of Liraglutide aloneCase report or seriesMechanism
In both reported cases following unspecified GLP-1 agonist use, nasal endoscopy showed loss of anterior eustachian-tube cushion tissue bulk.
In plain wordsIn both reported cases after unspecified GLP-1 medicine use, endoscopy showed loss of anterior eustachian-tube cushion tissue bulk.
Peptide
Liraglutide
Outcome
DecreaseAnterior eustachian tube cushion tissue bulk
Study
n = 2
Outcome group
Receptor activity and mechanism · Whole body
Source sentences
Summary
In both cases, nasal endoscopy confirmed significant loss of tissue bulk of the anterior and posterior ET cushions.
2 context sentences(design, population, supporting numbers)
Summary · context
We present autophony and aural fullness following GLP-1 agonist use.
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3966674321
30HumanNot a test of Semaglutide aloneCase report or seriesMechanism
In both reported cases following unspecified GLP-1 agonist use, nasal endoscopy showed loss of anterior eustachian-tube cushion tissue bulk.
In plain wordsIn both reported cases after unspecified GLP-1 medicine use, endoscopy showed loss of anterior eustachian-tube cushion tissue bulk.
Peptide
Semaglutide
Outcome
DecreaseAnterior eustachian tube cushion tissue bulk
Study
n = 2
Outcome group
Receptor activity and mechanism · Whole body
Source sentences
Summary
In both cases, nasal endoscopy confirmed significant loss of tissue bulk of the anterior and posterior ET cushions.
2 context sentences(design, population, supporting numbers)
Summary · context
We present autophony and aural fullness following GLP-1 agonist use.
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3966674322
31HumanNot a test of Liraglutide aloneCase report or seriesMechanism
In both reported cases following unspecified GLP-1 agonist use, nasal endoscopy showed loss of posterior eustachian-tube cushion tissue bulk.
In plain wordsIn both reported cases after unspecified GLP-1 medicine use, endoscopy showed loss of posterior eustachian-tube cushion tissue bulk.
Peptide
Liraglutide
Outcome
DecreasePosterior eustachian tube cushion tissue bulk
Study
n = 2
Outcome group
Receptor activity and mechanism · Whole body
Source sentences
Summary
In both cases, nasal endoscopy confirmed significant loss of tissue bulk of the anterior and posterior ET cushions.
2 context sentences(design, population, supporting numbers)
Summary · context
We present autophony and aural fullness following GLP-1 agonist use.
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3966674335
32HumanNot a test of Semaglutide aloneCase report or seriesMechanism
In both reported cases following unspecified GLP-1 agonist use, nasal endoscopy showed loss of posterior eustachian-tube cushion tissue bulk.
In plain wordsIn both reported cases after unspecified GLP-1 medicine use, endoscopy showed loss of posterior eustachian-tube cushion tissue bulk.
Peptide
Semaglutide
Outcome
DecreasePosterior eustachian tube cushion tissue bulk
Study
n = 2
Outcome group
Receptor activity and mechanism · Whole body
Source sentences
Summary
In both cases, nasal endoscopy confirmed significant loss of tissue bulk of the anterior and posterior ET cushions.
2 context sentences(design, population, supporting numbers)
Summary · context
We present autophony and aural fullness following GLP-1 agonist use.
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3966674336
33HumanNot a test of Liraglutide aloneCase report or seriesSafety outcome
In reported cases following unspecified GLP-1 agonist use, autophony was observed; the individual agents were not named.
In plain wordsIn reported cases after unspecified GLP-1 medicine use, hearing one's own voice loudly was observed; the individual medicines were not named.
Peptide
Liraglutide
Outcome
Not applicableAutophony
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
We present autophony and aural fullness following GLP-1 agonist use.
2 context sentences(design, population, supporting numbers)
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
Summary · context
In both cases, nasal endoscopy confirmed significant loss of tissue bulk of the anterior and posterior ET cushions.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3966674301
34HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome
In reported cases following unspecified GLP-1 agonist use, autophony was observed; the individual agents were not named.
In plain wordsIn reported cases after unspecified GLP-1 medicine use, hearing one's own voice loudly was observed; the individual medicines were not named.
Peptide
Semaglutide
Outcome
Not applicableAutophony
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
We present autophony and aural fullness following GLP-1 agonist use.
2 context sentences(design, population, supporting numbers)
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
Summary · context
In both cases, nasal endoscopy confirmed significant loss of tissue bulk of the anterior and posterior ET cushions.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3966674302
35HumanNot a test of Liraglutide aloneCase report or seriesSafety outcome
In reported cases following unspecified GLP-1 agonist use, aural fullness was observed; the individual agents were not named.
In plain wordsIn reported cases after unspecified GLP-1 medicine use, ear fullness was observed; the individual medicines were not named.
Peptide
Liraglutide
Outcome
Not applicableAural fullness
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
We present autophony and aural fullness following GLP-1 agonist use.
2 context sentences(design, population, supporting numbers)
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
Summary · context
In both cases, nasal endoscopy confirmed significant loss of tissue bulk of the anterior and posterior ET cushions.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3966674303
36HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome
In reported cases following unspecified GLP-1 agonist use, aural fullness was observed; the individual agents were not named.
In plain wordsIn reported cases after unspecified GLP-1 medicine use, ear fullness was observed; the individual medicines were not named.
Peptide
Semaglutide
Outcome
Not applicableAural fullness
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
We present autophony and aural fullness following GLP-1 agonist use.
2 context sentences(design, population, supporting numbers)
Summary · context
We explore the association between GLP-1 RAs with eustachian tube dysfunction (ETD) and patulous ETD (PETD) by review of cases, literature, and the FDA adverse event database (FAERS).
Summary · context
In both cases, nasal endoscopy confirmed significant loss of tissue bulk of the anterior and posterior ET cushions.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3966674304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

GLP-1 Receptor Agonist Induced Eustachian Tube Dysfunction: Database and Systematic Review of Otolaryngologic Adverse Events.

Summary

Results from this study36

Studies that did not test the peptide alone34

Version history

Subjects

Publication types

MeSH terms